1. In this randomized controlled trial of patients with heart failure and mildly decreased or preserved ejection fraction, finerenone treatment was associated with lower rates of worsening heart ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.

In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, semaglutide 2.4 mg improved symptoms, physical limitations, exercise function and reduced inflammation and body ...

The following is a summary of “Clinical Implications of Pretest Probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension,” published in the November 2024 issue of Cardiology by Reddy et ...

Background: Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure worldwide. However, no unequivocally effective treatment for HFpEF has been ...

Eli Lilly has reported comprehensive outcomes from the Phase III SUMMIT trial of tirzepatide for individuals with heart failure with preserved ejection fraction (HFpEF) and obesity. The double ...

The international SUMMIT trial enrolled a total of 731 adults, ages 40 years and older, who had been diagnosed with HFpEF and obesity at health centers in nine countries including the U.S.

Credit: Africa Studio/Shutterstock. Eli Lilly has reported comprehensive outcomes from the Phase III SUMMIT trial of tirzepatide for individuals with heart failure with preserved ejection fraction ...

demonstrating that tirzepatide significantly lowered the risk of worsening heart failure events in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. Additionally ...

“Now, these data, in combination with the STEP-HFpEF program, are really building this case that there's not just improvements in ‘function and feel’ endpoints, but really there’s this clinical ...

CHICAGO — A new study has shown for the first time that a drug therapy can reduce major heart failure clinical outcomes in patients with heart failure and a preserved ejection fraction (HFpEF ...

Tirzepatide reduced cardiovascular death or heart failure worsening by 38% in patients with obesity and HFpEF, compared to placebo. The trial showed significant weight loss and improved insulin ...